



#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

GARCIA-BLANCO et al

Atty. Ref.: 1579-321

Serial No. 09/465,802

Group:

Filed: December 17, 1999

Examiner:

For: ALTERNATIVE SPLICING OF FIBROBLAST GROWTH
FACTOR RECEPTOR 2 MRNA IN PROSTATE CANCER

* * * * *

March 31, 2000

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

REQUEST FOR CORRECTION OF FILING RECEIPT

Enclosed is a copy of the Filing Receipt for the above-identified application which incorrectly states information relating to Applicants. It now reads as "MARIANO A GARCIA-BLANCO, RESIDENCE NOT PROVIDED; RUSS P CARSTENS, RESIDENCE NOT PROVIDED". It should read as MARIANO A GARCIA-BLANCO, DURHAM, NC; RUSS P CARSTENS, DURHAM, NC. Also, this case is entitled to small entity status and same is requested to be indicated on the filing receipt. Further, in the title, the last word is misspelled. It now reads as "CANCEL". It should read as "CANCER".. The corrections are shown in red on the attached copy of the filing receipt. Please note your records accordingly. Correction of same is respectfully requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

MJW:tat
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

FILING RECEIPT


1579-321
msw



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
09/465,802	12/17/99	1642	\$0.00	1579-321	11	4	1

NIXON & VANDERHYDE PC
ATTORNEY AT LAW
1100 NORTH GLEBE ROAD 8TH FLOOR
ARLINGTON VA 22201-4714



Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the date presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts of Application" ("Missing Parts Notice") in this application, please submit any corrections to this Filing Receipt with your reply to the "Missing Parts Notice." When the PTO processes the reply to the "Missing Parts Notice," the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) **MARIANO A GARCIA-BLANCO, ~~RESIDENCE NOT PROVIDED~~; RUSS P CARSTENS, ~~RESIDENCE NOT PROVIDED~~. DURHAM, NC**

CONTINUING DATA AS CLAIMED BY APPLICANT-
PROVISIONAL APPLICATION NO. 60/112,856 12/17/98

* SMALL ENTITY *

IF REQUIRED, FOREIGN FILING LICENSE GRANTED 02/14/00

TITLE

ALTERNATIVE SPLICING OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 MRNA IN
PROSTATE ~~CANCER~~ **CANCER**

PRELIMINARY CLASS: 435

DATA ENTRY BY: HINES, BRENDA

TEAM: 06 DATE: 02/14/00

(See reverse for new important information)

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "FOREIGN FILING LICENSE GRANTED" followed by a date appears on the reverse side of this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.11. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR Parts 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "FOREIGN FILING LICENSE GRANTED" DOES NOT appear on the reverse side of this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE ---- The Following Information about the Filing Receipt:

The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.

The words "new," "improved," "improvement," "improvements in or relating to" are not included as the first words in the title of an application because a patent application is, by nature, a new idea or improvement.

The title may be truncated if it consists of more than 4 lines of 70 characters each (letters and spaces combined).

The inventor information may be truncated if the family name consists of more than 25 characters (letters and spaces combined) and if the given name consists of more than 25 characters (letters and spaces combined). The inventor's residence allows for up to 40 characters (letters and spaces combined).

The docket number allows a maximum of 12 characters.

If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Customer Address may have been modified to conform to U.S. Postal rules.

Please direct correction, including a copy of your Filing Receipt, to:
Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center